Overall survival (primary endpoint)
Primary endpoint met prespecified stopping criteria at interim analysis
(1-sided p<0.009279 at approximately 74% of events required for final analysis)
1.00
0.50
0.25
0
0.75
200
100
50
0
150
300
250
400
350
450
Days from randomization
Survival distribution function
Placebo N=255
Regorafenib N=505
Median 6.4 mos 5.0 mos
95% CI
5.9–7.3
4.4–5.8
Hazard ratio: 0.77
(95% CI: 0.64–0.94)
1-sided p-value: 0.0052
Regorafenib
Placebo
